Bone Cancer Drugs Market, By Drug Type ( Antimetabolites, Anthracyclines, Antibiotics, and Others ), By Disease Indication, By Distribution Channel, Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region

Description

Global bone cancer drugs market is estimated to be valued at US$ 1,286.4 Mn in 2023, and is expected to exhibit a CAGR of 5.2% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 1,286.4 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.20%	2030 Value Projection:	US$ 1,830.6 Mn

Global Bone Cancer Drugs Market Share (%), By Drug Type, 2023

The term "bone cancer" refers to a variety of malignancies that in the bones. Normal bone tissues may suffer damage, if the cancer cells spread into a bone. The type of bone cancer depends on the cell and tissue types where the disease first manifests itself. Primary bone malignancies are tumors that originate inside the bone itself. Many cancers that start in the body organs or other tissues can spread to the bones in addition to other body parts. These growths are referred to as metastatic or secondary bone malignancies. Most tumors that metastasis (spread) to the bones are from the breast, prostate, and lung. In bone cancer, abnormal cells in bone grow out of control and destroys the normal bone tissue. It can start in bone or spread to other parts of body (called metastasis). Bone cancer is rare. Most bone tumors are benign, and thus, these are not cancerous and will not spread to other areas of your body. However, these can weaken bones and lead to fractures or other problems. There are a few common types of benign bone tumors: Osteochondroma is the most common. It is common in people under the age of 20. A giant cell tumor is present in leg. In rare cases, these can also be cancerous. Osteoid osteomas often occur in long bones, usually in the early 20s. Osteoblastoma is a rare tumor that grows in the spine and long bones, and occurs primarily in young adults. Enchondromas usually appear in the bones of hands and feet. Often there are no symptoms. It is the most common type of hand tumor. Thus, increasing prevalence of bone cancer is expected to drive growth of the global bone cancer drugs market over the forecast period.

Market Dynamics

Increasing products and approvals by government regulatory bodies is expected to drive growth of the global bone cancer drugs market over the forecast period. For instance, in February 2021, the U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to the bone-targeting radiopharmaceutical samarium-153-DOTMP (CycloSam) for use as a potential therapeutic option for patients with osteosarcoma. The nuclear technology uses low specific activity samarium-153 thatreduces europium contamination, and DOTMP, a chelator designed to prevent off-target migration and at target sites with high bone turnover.

Key features of the study:

This report provides an in-depth analysis of the global bone cancer drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bone cancer drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co., Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd and Teva Pharmaceutical
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global bone cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drugs market

Detailed Segmentation:

Global Bone Cancer Drugs Market, By Drug Type:
- Antimetabolites
- Anthracyclines
- Antibiotics
- Others (RANK ligand inhibitors, etc.)
Global Bone Cancer Drugs Market, By Disease Indication:
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing's Sarcoma
Global Bone Cancer Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Bone Cancer Drugs Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Advaxis, Inc.
- Cellectar Biosciences, Inc.
- OPKO Health, Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Eli Lilly and Company
- Debiopharm Group
- Merck & Co
- Bayer AG
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical
- F. Hoffmann-La Roche Ltd
- Teva Pharmaceutical

Product Code: CMI93

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Drivers
Restraints
Opportunities
Market Trends
Regulatory Scenario
New Product Launches/Approvals
Merger, Acquisition and Collaboration Scenario
PEST Analysis
PORTER's Analysis

4. Global Bone Cancer Drugs Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Bone Cancer Drugs Market, By Drug Type, 2023- 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2023-2030
- Segment Trends
Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
Anthracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
Others (RANK ligand inhibitors, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)

6. Global Bone Cancer Drugs Market, By Disease Indication, 2023 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)
Osteosarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)
Chondrosarcoma
- Introduction
Ewing's Sarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Bone Cancer Drugs Market, By Distribution Channel, 2023 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2023-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)

8. Global Bone Cancer Drugs Market, By Region, 2023 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2023-2030
- Segment Trends
North America
- Market Size and Forecast,and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
- U.S.
- Canada
Europe
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2023-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa

9. Competitive Landscape

Company Profiles
- Advaxis, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Cellectar Biosciences, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- OPKO Health, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Pfizer Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Amgen Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Novartis AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Eli Lilly and Company
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Debiopharm Group
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Merck & Co
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Bayer AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Bristol-Myers Squibb Company
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Takeda Pharmaceutical
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- F. Hoffmann-La Roche Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Teva Pharmaceutical
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Analyst Views

10. Section

References
Research Methodology
About us and Sales Contact